Publications

• The Epidemiology of Atopic Dermatitis among Adults and Adolescents with Alopecia Areata in the United States.Bunick CG, Armstrong AW, Grada A, Soliman AM, Li C, Bristow CC, Khan IA, Lipiszko D, Silverberg JI, Issa NT, Mostaghimi A. J Invest Dermatol. 2026 Feb; 2025 Jun 26. PMID: 40581103.
• Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP).Bunick CG, Magnolo N, Moore A, Abe M, Gao X, Lynde C, Ibrahim N, Levy G, Calimlim BM, Wu X, Armendariz Y, Grada A, Eyerich K. Am J Clin Dermatol. 2026 Jan 14; 2026 Jan 14. PMID: 41533220.
• Outcomes in Bimekizumab Treated Psoriasis Patients With Prior IL-17 Inhibitor Failure.Song EJ, Pretorius P, Dasilva DR, Bunick CG, Liu C, Shahriari M. J Psoriasis Psoriatic Arthritis. 2026 Jan 8; 2026 Jan 8. PMID: 41523710.
• Decoding Genetic Disease Through the Skin: Lessons From the UDN Authors.Sivadas A, Moore K, Ezell K, McMinn A, Furuta Y, Bunick CG, Cassini T, Hamid R, Phillips JA 3rd, Tinker RJ. Int J Dermatol. 2026 Jan 7; 2026 Jan 7. PMID: 41496737.
• Seborrheic Dermatitis in the United States: Stable National Rates With Marked State-Level Variation, 2010-2021.Grada A, Cotter D, Shqair L, Akbarialiabad H, Ghannoum M, Bunick CG. Int J Dermatol. 2026 Jan 6; 2026 Jan 6. PMID: 41492699.
• Racial and Ethnic Disparities in Access to Advanced Therapies for Atopic Dermatitis in the United States.Abuabara K, Bunick CG, Lee LW, Grada A, Calimlim B, Mora AG, Cizenski J, Simpson B, Obi C, Goldberg R, Knapp KD, Munoz B, Perez AD, Crawford JM, Silverberg JI. J Drugs Dermatol. 2026 Jan 1. PMID: 41493253.
• Structural Basis for Differential Jak2 and Jak3 Kinase Selectivity of Ruxolitinib and Delgocitinib.Wang J, Bunick CG. J Invest Dermatol. 2026 Jan; 2025 Aug 16. PMID: 40825469.
• Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor.Mehrotra S, Sano Y, Halkowycz P, Wilson E, Durairaj C, Kong KF, Xia G, Dunbar F, Spector T, Heap GA, Bunick CG, McInnes IB. J Invest Dermatol. 2026 Jan; 2025 May 27. PMID: 40441292.
• Maximal use of 0.05% topical isotretinoin in patients with congenital ichthyosis results in low systemic exposure.Schneider H, Bunick CG, Hillmann K, Huynh TN, Kempers S, Peschel N, Blume-Peytavi U, Teng JMC, Mendelsohn AM, Stinson J, Lee LW. Br J Clin Pharmacol. 2025 Dec 17; 2025 Dec 17. PMID: 41406959.
• Empathy for the Patient with Chronic Hand Eczema.Tooks M, Bunick CG. Dermatol Ther (Heidelb). 2025 Dec 6; 2025 Dec 6. PMID: 41350514.
• Systemic Corticosteroid Use in Atopic Dermatitis: A Position Paper to Inform Safer Clinical Practice and Policy.Burshtein J, Bunick CG, Vleugels RA, Armstrong AW, Golant AK, Schlesinger T, Strober BE, Song EJ, Gold LS, Lebwohl M. J Invest Dermatol. 2025 Dec; 2025 Sep 6. PMID: 40914897.
• Biologic Therapies Targeting Type 2 Signaling in Atopic Dermatitis: A Comparative Review of Structural and Thermodynamic Differences in Mechanism of Action.Bunick CG. J Invest Dermatol. 2025 Dec; 2025 Aug 6. PMID: 40767793.
• A Justification to Using the FDA Adverse Event Reporting System for Hypothesis Generation Regarding Benzoyl Peroxide.Yang K, Bunick CG, Jafarian F. J Invest Dermatol. 2025 Dec; 2025 Jul 7. PMID: 40633753.
• A Triple-Action Inhibitory Mechanism of Allosteric TYK2-Specific Inhibitors.Wang J, Lomakin IB, Batista VS, Bunick CG. J Invest Dermatol. 2025 Dec; 2025 May 14. PMID: 40378946.
• Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-Analysis.Rønnstad ATM, Isufi D, Bunick CG, Chovatiya R, Nielsen ML, Alinaghi F, Thomsen SF, Vestergaard C, Wollenberg A, Egeberg A, Thyssen JP, Loft N. Am J Clin Dermatol. 2025 Nov 26; 2025 Nov 26. PMID: 41296263.
• Publisher Correction: Risk of Nonmelanoma Skin Cancer in Patients with Moderate-to-Severe Atopic Dermatitis: A United States Population-Based Study.Lebwohl M, Yue E, Krueger WS, Berman B, Bunick CG, Schlesinger T, Grada A. Dermatol Ther (Heidelb). 2025 Nov 26; 2025 Nov 26. PMID: 41296217.
• Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years.Bunick CG, Irvine AD, Silverberg JI, Guttman-Yassky E, Shahriari M, Gao X, Weidinger S, Katoh N, Vigna N, Dilley DM, D'Andrea E, Teixeira HD, Platt AM, Levy GF. J Eur Acad Dermatol Venereol. 2025 Nov 15; 2025 Nov 15. PMID: 41239921.
• Pustular psoriasis following treatment with biologics among patients with plaque psoriasis: a nationwide cohort study.Loft N, Zachariae C, Kaur-Knudsen D, Bunick CG, Gilliet M, Skov L. Br J Dermatol. 2025 Nov 8; 2025 Nov 8. PMID: 41206720.
• Advances in Cell-Mediated Drug Delivery for Dermatologic Diseases: Mechanisms and Current Applications.Shqair L, Draw I, Maya T, Bunick CG, Akbarialiabad H, Schlesinger T, Damiani G, Ghannoum M, Grada A. Pharmaceutics. 2025 Nov 7; 2025 Nov 7. PMID: 41304776.
• Author Correction: Enhancing randomized clinical trials with digital twins.Akbarialiabad H, Pasdar A, Murrell DF, Mostafavi M, Shakil F, Safaee E, Leachman SA, Haghighi A, Tarbox M, Bunick CG, Grada A. NPJ Syst Biol Appl. 2025 Nov 6; 2025 Nov 6. PMID: 41198687.
• Correction to: Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double‑Blind, Phase 3 Trials.Bissonnette R, Albreiki F, Ehst BD, Al Hammadi A, Schliemann S, Yang B, Zhang J, Bunick CG. Am J Clin Dermatol. 2025 Nov 1; 2025 Nov 1. PMID: 41175337.
• Response to Veenstra et al's "Benzoyl peroxide acne treatment shows no significant association with benzene-related cancers: A multicenter retrospective analysis" on statistical design.Bunick CG, Yang K, Jafarian F, Barbieri JS. J Am Acad Dermatol. 2025 Oct 13; 2025 Oct 13. PMID: 41093062.
• Risk of Nonmelanoma Skin Cancer in Patients with Moderate-to-Severe Atopic Dermatitis: A United States Population-Based Study.Lebwohl M, Yue E, Krueger WS, Berman B, Bunick CG, Schlesinger T, Grada A. Dermatol Ther (Heidelb). 2025 Oct 13; 2025 Oct 13. PMID: 41082088.
• Enhancing randomized clinical trials with digital twins.Akbarialiabad H, Pasdar A, Murrell DF, Mostafavi M, Shakil F, Safaee E, Leachman SA, Haghighi A, Tarbox M, Bunick CG, Grada A. NPJ Syst Biol Appl. 2025 Oct 3; 2025 Oct 3. PMID: 41044102.
• IL-17 Class Inhibitors and Plaque Psoriasis: Not All Biologics Relapse Equally.Issa NT, Al-Tariq K, Bunick CG. J Clin Aesthet Dermatol. 2025 Oct. PMID: 41416024.
• INDIVIDUAL ARTICLE: The Utility of Delgocitinib in Chronic Hand Eczema.Issa NT, Yu J, Bunick CG, Kircik L. J Drugs Dermatol. 2025 Oct 1. PMID: 41037535.
• When topicals fall short, oral Janus kinase inhibitors offer a needed solution in chronic hand eczema.Bunick CG. JAAD Int. 2025 Oct; 2025 Jul 17. PMID: 40831621.
• Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 Trials.Bissonnette R, Albreiki F, Ehst BD, Al Hammadi A, Schliemann S, Yang B, Zhang J, Bunick CG. Am J Clin Dermatol. 2025 Sep 26; 2025 Sep 26. PMID: 41006920.
• Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% to Treat Acne Induced by Janus Kinase Inhibitor Treatment: A Case Report.Olszewski N, Bunick CG. J Clin Aesthet Dermatol. 2025 Sep. PMID: 41416232.
• Nemolizumab Demonstrates Marked Efficacy in Challenging Chronic Pruritus: A Real-world Multicenter Case Series.Dasilva DR, Soto-González A, Mollanazar NK, Ndubisi S, Issa N, Song JE, Shahriari M, Bunick CG, Lio P, Nguyen HP, Yosipovitch G, Del Rosso J. J Clin Aesthet Dermatol. 2025 Sep. PMID: 41416230.
• Space Oncology: A Comprehensive Scoping Review.Niknam N, Akbarialiabad H, Farjoud Kouhanjani M, Kolaparambil Varghese LJ, Berrington de González A, Melin MM, Shafie'ei M, Mousavi SM, Hosseini SA, Taha SR, Russomano T, Murrell DF, Grada A, Leachman SA, Akbari Z, Derisi AJ, Jurga M, Kumar A, Das S, D'Urbano J, Hakim G, Sadeghian N, Paydar S, Tarbox M, West C, Ghorashi SM, Hosseini SH, Squire T, Bunick CG, Christiansen R. Wilderness Environ Med. 2025 Sep; 2025 Jul 13. PMID: 40653854.
• A Disproportionality Analysis on Benzoyl Peroxide and Its Risk of Malignancy Using the FDA Adverse Event Reporting System.Yang K, Czyz S, Zuberi R, Kreutz J, Bunick CG, Jafarian F. J Invest Dermatol. 2025 Sep; 2025 Mar 7. PMID: 40058570.
• Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic Dermatitis.Silverberg JI, Gooderham M, Wollenberg A, Pink AE, Ruiz Dasilva D, Kwatra SG, Binamer Y, Katoh N, Aoki V, Moreira A, Grada A, Li C, Calimlim B, Lee WJ, Bunick CG. Dermatol Ther (Heidelb). 2025 Aug; 2025 Jun 26. PMID: 40569545.
• Benzoyl Peroxide-Containing Products and Benzene: Where Are We Now After Recalls, and How Should We Move Forward?Barbieri JS, Bunick CG. JAMA Dermatol. 2025 Aug 1. PMID: 40531498.
• Revisiting RORγt Inhibition in Plaque Psoriasis: Lessons Learned from BI 730357.Akbarialiabad H, Bunick CG. J Invest Dermatol. 2025 Aug; 2025 May 27. PMID: 40423599.
• Response to Barbieri et al.Kucera K, Bunick CG, Light DY. J Invest Dermatol. 2025 Aug; 2025 Feb 19. PMID: 39983978.
• The skin microbiome in dermatologic disease.MacGibeny MA, Adjei S, Pyle H, Bunick CG, Ghannoum M, Grada A, Harris-Tryon T, Tyring SK, Kong HH. J Am Acad Dermatol. 2025 Aug; 2024 Aug 20. PMID: 39173885.
• The human skin microbiome in health.MacGibeny MA, Adjei S, Pyle H, Bunick CG, Ghannoum M, Grada A, Harris-Tryon T, Tyring SK, Kong HH. J Am Acad Dermatol. 2025 Aug; 2024 Aug 19. PMID: 39168311.
• Structural Insights: What Makes Some PDE4 Inhibitors More Effective in Inflammatory Dermatoses.Issa NT, Wang J, Hanly A, Ho M, Obagi S, Damiani G, Del Rosso JQ, Kang Y, Bunick CG. J Clin Aesthet Dermatol. 2025 Jul 1. PMID: 40778010.
• Treating Chronic Hand Eczema with Upadacitinib: Insights from Clinical Trials and Real-World Experience.Alani O, Shqair L, Liszewski WJ, Yu H, Draw I, Wahood S, Galimberti F, Sweney B, Obagi S, Mastro A, Dasilva D, Bunick CG. J Drugs Dermatol. 2025 Jul 1. PMID: 40627583.
• Surface keratin 1, a tumor-selective peptide target in human triple-negative breast cancer.Yao SJ, Amirrad F, Ziaei E, Saghaeidehkordi A, Roosan MR, Shamloo K, Sharma A, Sumbria RK, Nauli SM, Bunick CG, Kaur K. Sci Rep. 2025 Jul 1; 2025 Jul 1. PMID: 40595898.
• Correction to: Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis.Rønnstad ATM, Bunick CG, Chovatiya R, Kamata M, Nielsen ML, Isufi D, Thomsen SF, Vestergaard C, Wollenberg A, Egeberg A, Thyssen JP, Loft N. Am J Clin Dermatol. 2025 Jul. PMID: 40272773.
• PDE4 Inhibitors: Bridging Molecular Insights With Clinical Impact.Issa NT, Obagi S, Damiani G, Wang J, Bunick CG. J Drugs Dermatol. 2025 Jun 1. PMID: 40465498.
• Chemical, Biochemical, and Structural Similarities and Differences of Dermatological cAMP Phosphodiesterase-IV Inhibitors.Wang J, Ho M, Bunick CG. J Invest Dermatol. 2025 Jun; 2024 Nov 27. PMID: 39608668.
• Fluoroquinolones for Dermatologists: A Practical Guide to Clinical Use and Risk Management.Wahood S, Alani O, Draw I, Shqair L, Wang D, Bunick CG, Damiani G, Ho JD, Obagi S, Akbarialiabad H, Galimberti F, Ghannoum M, Grada A. Pharmaceuticals (Basel). 2025 May 26; 2025 May 26. PMID: 40573197.
• Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series.Greenberg ABW, Shahriari M, Cameron MC, Payette M, Dasilva DR, Damiani G, Herman EI, Eminger LA, Issa NT, Rodriguez A, Del Rosso JQ, Kang Y, Cohen JM, Bunick CG. J Clin Aesthet Dermatol. 2025 May 1. PMID: 40538523.
• Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis.Alani O, Wang D, Wahood S, Obagi S, Dasilva D, Zirwas MJ, Galimberti F, Bunick CG. J Drugs Dermatol. 2025 May 1. PMID: 40327575.
• Leveraging space innovations for cancer breakthroughs on Earth.Akbarialiabad H, Jamshidi P, Aminzade Z, Azizi N, Taha SR, Sadeghian N, Varghese LJK, Kouhanjani MF, Niknam N, Babocs D, El-Assaad F, Russomano T, Murrell DF, Paydar S, Bunick CG, Christiansen R, Mark Melin M. Trends Cancer. 2025 May; 2025 Mar 12. PMID: 40082142.
• Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis.Rønnstad ATM, Bunick CG, Chovatiya R, Kamata M, Nielsen ML, Isufi D, Thomsen SF, Vestergaard C, Wollenberg A, Egeberg A, Thyssen JP, Loft N. Am J Clin Dermatol. 2025 May; 2025 Mar 5. PMID: 40045152.
• Evaluation of Benzene Presence and Formation in Benzoyl Peroxide Drug Products.Kucera K, Zenzola N, Hudspeth A, Dubnicka M, Hinz W, Bunick CG, Girardi M, Dabestani A, Light DY. J Invest Dermatol. 2025 May; 2024 Oct 7. PMID: 39384016.
• Autosomal dominant SLURP1 variants cause palmoplantar keratoderma and progressive symmetric erythrokeratoderma.Jiang X, Mortlock RD, Lomakin IB, Zhou J, Hu R, Cossio ML, Bunick CG, Choate KA. Br J Dermatol. 2025 Apr 28. PMID: 39913669.
• Psoriasis: Perspectives from Irwin M. Braverman, MD.Cohen JM, Bunick CG. Clin Dermatol. 2025 Mar-Apr; 2024 Dec 21. PMID: 39716549.
• INDIVIDUAL ARTICLE: Appraisal of Ruxolitinib 1.5% Cream as a First-Line Topical Therapeutic Agent for Adolescents and Adults With Mild-to-Moderate Atopic Dermatitis.Issa NT, Kwong P, Bunick CG, Kircik L. J Drugs Dermatol. 2025 Feb 1. PMID: 39913233.
• INDIVIDUAL ARTICLE: Ruxolitinib 1.5% Cream and the "Boxed Warning Paradox": Reappraisal of Safety Through the Lens of Pharmacokinetics.Issa NT, Kwong P, Bunick CG, Kircik L. J Drugs Dermatol. 2025 Feb 1. PMID: 39913232.
• Practical Guide for Implementing Cryogenic Electron Microscopy Structure Determination in Dermatology Research.Lomakin IB, Devarkar SC, Freniere C, Bunick CG. J Invest Dermatol. 2025 Jan; 2024 Nov 26. PMID: 39601740.
• Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up).Silverberg JI, Bunick CG, Hong HC, Mendes-Bastos P, Stein Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Calimlim B, Eyerich K. Br J Dermatol. 2024 Dec 23. PMID: 39438067.
• Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry.Silverberg JI, Calimlim BM, Grada A, Bunick CG, Gooderham MJ, Shi VY, Obi C, Knapp KD, Munoz B, Crawford JM, Paller AS. J Dermatolog Treat. 2024 Dec; 2024 Dec 11. PMID: 39662888.
• Mechanistic Basis for the Translation Inhibition of Cutibacterium acnes by Clindamycin.Lomakin IB, Devarkar SC, Grada A, Bunick CG. J Invest Dermatol. 2024 Nov; 2024 Aug 8. PMID: 39122144.
• Crystal Structure of Bimekizumab Fab Fragment in Complex with IL-17F Provides Molecular Basis for Dual IL-17A and IL-17F Inhibition.Adams R, Bunick CG, Lawson ADG, Gomez B, Shaw S. J Invest Dermatol. 2024 Nov; 2024 Apr 16. PMID: 38631666.
• Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis.Lain ET, Bhatia N, Kircik L, Gold LS, Harper JC, Bunick CG, Guenin E, Baldwin H, Feldman SR, Rosso JQD. J Drugs Dermatol. 2024 Oct 1. PMID: 39361705.
• Structural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis.Daniele SG, Galimberti F, Bunick CG. J Drugs Dermatol. 2024 Oct 1. PMID: 39361690.
• In response to Reynolds et al's "guidelines of care for the management of acne vulgaris".Issa NT, Bunick CG. J Am Acad Dermatol. 2024 Oct; 2024 Jun 21. PMID: 38909659.
• Clindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology.Del Rosso JQ, Armillei MK, Lomakin IB, Grada A, Bunick CG. J Clin Aesthet Dermatol. 2024 Aug. PMID: 39148960.
• Rapid Remission of Plaque Psoriasis With Bimekizumab Treatment.Abdin R, Gharib R, Bunick CG, Issa NT. J Drugs Dermatol. 2024 Aug 1. PMID: 39093648.
• Topical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances.Del Rosso JQ, Bunick CG, Kircik L, Bhatia N. J Drugs Dermatol. 2024 Jun 1. PMID: 38834223.
• Unveiling the secrets of vimentin filament architecture relevant to human disease.Lomakin IB, Ho M, Bunick CG. Nat Struct Mol Biol. 2024 Jun. PMID: 38684931.
• Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis.Kircik LH, Stein Gold L, Gold M, Weiss JS, Harper JC, Del Rosso JQ, Bunick CG, Bhatia N, Tanghetti EA, Eichenfield LF, Baldwin H, Draelos ZD, Callender VD, Han G, Gooderham MJ, Sadick N, Lupo MP, Lain ET, Werschler WP. Dermatol Ther (Heidelb). 2024 May; 2024 May 9. PMID: 38724841.
• Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).Silverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS, Hijnen D, Calimlim BM, Lee WJ, Teixeira HD, Hu X, Zhang S, Yang Y, Grada A, Platt AM, Thaçi D. Am J Clin Dermatol. 2024 May; 2024 Mar 25. PMID: 38528257.
• Altered skin microbiome, inflammation, and JAK/STAT signaling in Southeast Asian ichthyosis patients.Ho M, Nguyen HN, Van Hoang M, Bui TTT, Vu BQ, Dinh THT, Vo HTM, Blaydon DC, Eldirany SA, Bunick CG, Bui CB. Hum Genomics. 2024 Apr 16; 2024 Apr 16. PMID: 38627868.
• Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease.Armillei MK, Lomakin IB, Del Rosso JQ, Grada A, Bunick CG. Antibiotics (Basel). 2024 Mar 17; 2024 Mar 17. PMID: 38534705.
• Rethinking Hidradenitis Suppurativa Management: Insights into Bacterial Interactions and Treatment Evolution.Huynh FD, Damiani G, Bunick CG. Antibiotics (Basel). 2024 Mar 17; 2024 Mar 17. PMID: 38534703.
• Benzoyl Peroxide Drug Products Form Benzene.Kucera K, Zenzola N, Hudspeth A, Dubnicka M, Hinz W, Bunick CG, Dabestani A, Light DY. Environ Health Perspect. 2024 Mar; 2024 Mar 14. PMID: 38483533.
• Structural Basis for p19 Targeting by Anti-IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis.Daniele SG, Eldirany SA, Damiani G, Ho M, Bunick CG. JID Innov. 2024 Mar; 2024 Jan 20. PMID: 38445231.
• Triple-action inhibitory mechanism of allosteric TYK2-specific inhibitors.Wang J, Batista VS, Bunick CG. bioRxiv. 2023 Oct 9; 2023 Oct 9. PMID: 37873392.
• Ensuring Dermatologists Practice Enhanced Antibiotic Stewardship With Sarecycline Mnemonic.Borash J, Bunick CG, Graber E. J Drugs Dermatol. 2023 Oct 1. PMID: 37801533.
• Circadian Oscillations of Minimal Erythema Dose (MED) are Also Influenced by Diet in Patients with Psoriasis: A Chronomedical Study.Damiani G, Pacifico A, Scoditti E, di Gregorio S, Del Fabbro M, Cozzolino C, Buja A, Mercuri SR, Bianchi VG, Grada A, Garbarino S, Bunick CG. Dermatol Ther (Heidelb). 2023 Oct; 2023 Aug 12. PMID: 37573289.
• Acne accounts for an almost 2.5-fold higher proportion of dermatology visits among adult females compared to adult males in the United States: A study of the national ambulatory medical care survey from 2002-2016.Chang J, Nock MR, Cohen JM, Bunick CG. PLoS One. 2023; 2023 Sep 21. PMID: 37733776.
• Antimicrobial Wound Dressings: A Concise Review for Clinicians.Yousefian F, Hesari R, Jensen T, Obagi S, Rgeai A, Damiani G, Bunick CG, Grada A. Antibiotics (Basel). 2023 Sep 11; 2023 Sep 11. PMID: 37760730.
• Congenital Ichthyosis: A Practical Clinical Guide on Current Treatments and Future Perspectives.Lilly E, Bunick CG. Clin Cosmet Investig Dermatol. 2023; 2023 Sep 11. PMID: 37719935.
• Demystifying Hand Eczema.Grada A, Bunick CG. J Invest Dermatol. 2023 Aug; 2023 Apr 27. PMID: 37115112.
• Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study.Bunick CG, Teng JMC, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn AM, Raiz J, Murrell DF. Clin Exp Dermatol. 2023 Jul 7. PMID: 36928932.
• Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis.Murrell DF, Teng JMC, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn AM, Raiz J, Bunick CG. Clin Exp Dermatol. 2023 Jun 5. PMID: 36794376.
• Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study.Marathe K, Teng JMC, Guenthner S, Bunick CG, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn AM, Raiz J, Murrell DF. Dermatol Ther (Heidelb). 2023 Jun; 2023 May 11. PMID: 37170057.
• Sarecycline inhibits protein translation in Cutibacterium acnes 70S ribosome using a two-site mechanism.Lomakin IB, Devarkar SC, Patel S, Grada A, Bunick CG. Nucleic Acids Res. 2023 Apr 11. PMID: 36864821.
• Inguinal patch in mpox (monkeypox) virus infection and eccrine syringometaplasia: report of two cases with in situ hybridization and electron microscopy findings.Roy SF, Sarhan J, Liu X, Murphy MJ, Bunick CG, Choate KA, Damsky WB, McNiff JM. Br J Dermatol. 2023 Mar 30. PMID: 36763786.
• Structural basis for differential p19 targeting by IL-23 biologics.Daniele SG, Eldirany SA, Ho M, Bunick CG. bioRxiv. 2023 Mar 9; 2023 Mar 9. PMID: 36945513.
• Trends in Oral Antibiotic Use for Acne Treatment: A Retrospective, Population-Based Study in the United States, 2014 to 2016.Grada A, Armstrong A, Bunick C, Salem R, Feldman S. J Drugs Dermatol. 2023 Mar 1. PMID: 36877883.
• Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management.Daniele SG, Kim SR, Grada A, Moore AY, Suozzi KC, Bunick CG. Am J Clin Dermatol. 2023 Mar; 2022 Dec 20. PMID: 36539678.
• Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity.Grada A, Del Rosso JQ, Moore AY, Stein Gold L, Harper J, Damiani G, Shaw K, Obagi S, Salem RJ, Tanaka SK, Bunick CG. Front Med (Lausanne). 2022; 2022 Dec 8. PMID: 36569144.
• JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies.Daniele S, Bunick C. J Drugs Dermatol. 2022 Dec 1. PMID: 36468956.
• The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis.Teng JMC, Bunick CG, Guenthner S, Murrell DF, Marathe K, Kempers S, Eads K, Mendelsohn AM, Raiz J, Tavakkol A, Castelo-Soccio L. J Am Acad Dermatol. 2022 Dec; 2022 Jul 21. PMID: 35872261.
• Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study.Paller AS, Browning J, Parish LC, Bunick CG, Rome Z, Bhatia N. J Am Acad Dermatol. 2022 Nov; 2022 Mar 7. PMID: 35271936.
• Stenotrophomonas maltophilia, a Pathogen of Increasing Relevance to Dermatologists: A Case Report and Review of the Literature.Belzer A, Weiss E, Etaee F, Bunick CG, Damsky W, Nelson CA. Antibiotics (Basel). 2022 Oct 12; 2022 Oct 12. PMID: 36290055.
• Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris.Swallow MA, Fan R, Cohen JM, Bunick CG. Antibiotics (Basel). 2022 Jul 30; 2022 Jul 30. PMID: 36009899.
• Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology.Grada A, Ghannoum MA, Bunick CG. Antibiotics (Basel). 2022 May 27; 2022 May 27. PMID: 35740129.
• Sarecycline treatment for acne vulgaris: Rationale for weight-based dosing and limited impact of food intake on clinical efficacy.Grada A, Del Rosso JQ, Graber E, Bunick CG, Stein Gold L, Moore AY, Baldwin H, Obagi Z, Damiani G, Carrothers T, McNamee B, Hanze E. Dermatol Ther. 2022 Mar; 2021 Dec 30. PMID: 34923732.
• Sarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal Microbiota.Ghannoum MA, Long L, Bunick CG, Del Rosso JQ, Gamal A, Tyring SK, McCormick TS, Grada A. Antibiotics (Basel). 2022 Feb 28; 2022 Feb 28. PMID: 35326788.
• Update of the keratin gene family: evolution, tissue-specific expression patterns, and relevance to clinical disorders.Ho M, Thompson B, Fisk JN, Nebert DW, Bruford EA, Vasiliou V, Bunick CG. Hum Genomics. 2022 Jan 6; 2022 Jan 6. PMID: 34991727.
• Keratin 1 as a cell-surface receptor in cancer.Ogunnigbagbe O, Bunick CG, Kaur K. Biochim Biophys Acta Rev Cancer. 2022 Jan; 2021 Dec 7. PMID: 34890750.
• Genotype‒Structurotype‒Phenotype Correlations in Patients with Pachyonychia Congenita.Wu TT, Eldirany SA, Bunick CG, Teng JMC. J Invest Dermatol. 2021 Dec; 2021 Jun 8. PMID: 34116063.